This volume provides an insight into the future strategies for commercial biocatalysis with a focus on sustainable technologies together with chemoenzymatic and biotechnological approaches to synthesize various types of approved and new active pharmaceutical ingredients (APIs) via proven and latest synthetic routes using single-step biocatalytic or enzyme cascade reactions. Many of these drugs act as enzyme inhibitors as discussed in a chapter with a variety of examples. The targeted enzymes are involved in diseases such as different cancers metastatic and infectious diseases osteoporosis and cardiovascular disorders. The biocatalysts employed for API synthesis include hydrolytic enzymes alcohol dehydrogenases laccases imine reductases reductive aminases peroxygenases cytochrome P450 enzymes polyketide synthases transaminases and halogenases. Many of them have been improved with respect to their properties by engineering methods. The book discusses the syntheses of drugs including alkaloids and antibiotics non-ribosomal peptides antimalarial and antidiabetic drugs prenylated xanthones antioxidants and many important (chiral) intermediates required for the synthesis of pharmaceuticals. |Pharmaceutical Biocatalysis Chemoenzymatic Synthesis of Active Pharmaceutical Ingredients | Science Client Lines
